CLINICAL_TRIALS
ClinicalTrials.gov record update
An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03801278
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:38:22.290066+00:00
- Published At
- 2021-12-13T00:00:00+00:00
- Record Updated At
- 2021-12-13
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Recurrent Bladder Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2021-12-13"- protocolSection.identificationModule.nctId
"NCT03801278"- protocolSection.identificationModule.officialTitle
"An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer"- protocolSection.statusModule.overallStatus
"NO_LONGER_AVAILABLE"- protocolSection.designModule.phases
[]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.